The first-in-human application of 68Gallium [68Ga]HER2-nanobody showed a favorable biodistribution, with the highest uptake in the kidneys, liver, and intestines and low background levels in other organs that generally harbor tumor lesions [34]. The gene discussed is ERBB2; the disease is neoplasm.